A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)

Clinical trial NCT07064122 · RECRUITING

Trial details

NCT number: NCT07064122
Sponsor: AstraZeneca
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Haematologic Neoplasms

Start date: 2025-11-03
Primary completion: 2028-10-20
Enrollment: 72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.